46 results about "Hypotensive drug" patented technology

A process for efficiently, easily and stably producing tripeptides Val-Pro-Pro and Ile-Pro-Pro, which are useful as hypotensive drugs, anti-stress drugs, etc., by an enzymatic method. This process involves the step of cleaving a milk casein-containing material with a proteinase to form an intermediate peptide selected from the group consisting of a peptide containing the sequence Val-Pro-Pro but having no Pro other than this sequence, a peptide containing the sequence Ile-Pro-Pro but having no Pro other than this sequence, and a mixture of these peptides, and then cleaving the intermediate peptide with a peptidase to thereby give at least one of the tripeptides Val-Pro-Pro and Ile-Pro-Pro.

The invention provides a method for synchronous detection of multiple residual drugs in a water environment, and belongs to the technical field of pollutant enrichment detection in a water environment. The residual drugs include antibiotics, anti-inflammatory analgesics and antihypertensive drugs, etc., and the synchronous detection method includes the following steps: (1) water sample pretreatment: filter to remove suspended matter, adjust the pH value of the water sample; (2) solidify Phase extraction: use HLB solid-phase extraction column to enrich the target drug; (3) blow nitrogen to nearly dry, dilute to 1mL and vortex for testing; (4) use LC-MS / MS for detection on the machine. The synchronous detection method of the present invention can simultaneously detect 32 pharmaceutical pollutants in the water body by one-time sample injection, and the method has the advantages of high accuracy and sensitivity and low detection limit; meanwhile, the method is environmentally friendly and easy to operate.

The invention relates to a noninvasive continuous blood pressure measuring method, comprising the following steps: acquiring a synchronizing signal of electrocardio and pulse waves of a subject; performing smoothing processing on the synchronizing signal of electrocardio and pulse waves of the subject, detecting an electrocardio signal R wave peak value point and characteristic points of the pulse waves and marking positions, calculating to obtain conducting time of the pulse wave and conduction ratio of corresponding pulse wave; and bringing the conducting time and conduction ratio of the pulse wave into an individualized blood pressure parameter model, and calculating to obtain continuous systolic pressure of the subject. A new parameter, that is conduction ratio, is introduced in the existing noninvasive blood pressure model, and an individualized parameter model is established for each subject, so as to obtain more accurate blood pressure results. The method is simple in operation, high in accuracy, and provides important basis for clinic blood pressure monitoring, home monitoring, and early warning, and monitoring of hypotensive drugs.

The invention relates to a pharmaceutical composition containing one of angiotensin converting enzyme inhibitors (ACEI) and active metabolites or medical salt thereof in medicine dosage, one or more of B vitamins in medicine dosage, ginkgo biloba extracts (GbE) in medicine dosage and a medical carrier, and relates to application of the pharmaceutical composition in preparing medicines for treating, preventing or retarding stroke. The medicines prepared by the pharmaceutical composition provided by the invention are superior to the simple antihypertensive drugs in the aspect of treating, preventing or retarding stroke and facilitate the patients to take. The invention belongs to the pharmaceutical field.

The invention relates to a dual-PPG (Photoplethysmography)-based blood pressure measuring method and device. The method comprises the following steps: penetrating human tissues by using projection light, wherein the influence factor of the light absorption of the human tissues can be obtained according to a Beer-Lambert law: log(I0 / I)=epsilonCl; reflecting the change of blood volume through a PPG signal; calculating the blood pressure by using PTT (Push to Talk). The method and the device have the advantages that self-detection can be realized through the blood pressure measurement based on PPG, and the all-day blood pressure can be better monitored based on continuous blood pressure monitoring of PPG in order to reflect the diurnal change situation of the blood pressure. The method and the device have important significance to the prevention of sudden cardiovascular diseases. Through the continuous blood pressure measurement based on PPG, the treatment of hypotensive drugs can be well monitored. Compared with other continuous blood pressure measurement, the continuous blood pressure measurement way based on PPG has remarkable advantages.

The invention discloses a preparation method of a dihydropyridine compound (IV), comprising the following steps: using a compound VII and a compound VIII as initial raw materials and carrying out a cyclization reaction in a solvent to prepare an intermediate IX; and (2) putting the compound IX in a solvent and removing protective groups to prepare the compound IV. The protective groups used in the invention are common, the raw materials are easily available, and poisonous and harmful substances are not generated after the protective groups are removed. In addition, the operation is simple, a reagent used for removing the protective groups is cheap and easily available, the operation is convenient, the post-treatment is simple, costs are low, environmental pollution is little, and the preparation method is suitable for industrial production. The preparation method provided by the invention has advantages of high yield, stable product quality, low cost and simple operation, and is suitable for industrial preparation of a hypotensive drug Cleviprex key intermediate. An equation is shown in the specification.

The invention relates to a preparation method of a sacubitril intermediate, in particular to a preparation method of R-diphenyl alaninol. The preparation method comprises the following steps: performing a reaction on a D-tyrosine derivative serving as a raw material and different substituted sulfonyl chloride (or anhydride) to obtain a compound as shown in a formula III, and preparing the R-diphenyl alaninol by using the compound as shown in the formula III through two routes. The route I is that the compound as shown in the formula III is reduced into a compound as shown in a formula II and the compound as shown in a formula II is coupled to obtain the R-diphenyl alaninol; and the route II is that the compound as shown in the formula III is coupled to obtain a compound as shown in a formula V and reduction is performed to obtain the R-diphenyl alaninol. The compound R-diphenyl alaninol prepared by the method is a key intermediate of one component sacubitril (AHU-377) of a novel pressure-reducing medicine LCZ696 (Entresto). The method is simple to operate, short in route and suitable for industrialized production. (The formulas are as shown in the description.).

The invention provides a hypotensive drug and a preparation method thereof. The hypotensive drug comprises the following components in parts by weight: 200-400 parts of kudzuvine root, 200-400 parts of red sage root, 80-150 parts of ligusticum wallichii, 200-400 parts of astragalus, 100-250 parts of cassia seed, 200-400 parts of crataegus pinnatifida, 100-250 parts of prunella vulgaris, 100-250 parts of rhodiola rosea, 30-70 parts of leech, 200-400 parts of codonopsis pilosula, 30-70 parts of ganoderma lucidum, 30-70 parts of ginseng or American ginseng, and 80-150 parts of gynostemma pentaphylla. The preparation method comprises the steps of weighing raw materials; preparing powder from each raw material; mixing all raw materials to obtain a first mixture; preparing pills from the first mixture; baking the pills; packaging. The hypotensive drug can play a good blood pressure reduction effect, is small in side effect, and has the effects of calming and preventing angiosclerosis.

The invention provides potassium-free sodium-reducing granulated edible salt. The potassium-free sodium-reducing granulated edible salt comprises the following components in percentage by weight: 50-75% of sodium chloride, 1-30% of yeast extract and the balance of auxiliary materials, wherein the sum of the weight percentages of the components is 100%. The potassium-free sodium-reducing granulatededible salt is designed according to the principle that saltiness and freshness are synergistic and salt is reduced but flavor is not reduced; under the condition that potassium chloride is not added, the purpose of reducing the salt by more than 25% can be achieved; the potassium-free sodium-reducing granulated edible salt is different from common sodium-reducing salt added with the potassium chloride in the market; due to the fact that the potassium chloride is not added, the sodium-reducing salt is also suitable for hypertension patients who take hypotensive drugs, and is more widely available than the common sodium-reducing salt. Through a granulating process, the sodium-reducing salt is more attractive in appearance and more convenient to use; and meanwhile, an anti-caking agent doesnot need to be added.

The invention provides a preparation method for Sacubitril as one component of a novel hypotensive drug Entresto. According to the method, chiral synthons, obtained in the oxydative degradation wastes of steroid sapogenin, are adopted as raw materials. The raw materials are subjected to five steps of reactions, and then the high-yield synthesis of Sacubitril is realized. The raw materials of the method are simple, easily available and low in cost. Meanwhile, the synthetic method is characterized by being mild in condition, simple in operation, high in yield and few in by-product. The method can be applied to the industrial production.

The invention provides 2″-hydroxynicotianamine; a method for producing 2″-hydroxynicotianamine comprising the step of obtaining an extract solution from a buckwheat sample followed by obtaining a fraction having an inhibitory activity for the angiotensin-converting enzyme by ion-exchange chromatography using an anion exchange resin; novel substances having an ACE inhibitory activity by preparing an inhibitor for the angiotensin-converting enzyme, a vasodepressor agent and a health food each containing 2″-hydroxynicotianamine; methods for producing the novel substances; an inhibitor for the angiotensin-converting enzyme and a vasodepressor agent having the novel substance as an effective ingredient; and a health food containing the novel substance.

The invention relates to a pharmaceutical composition containing angiotensin II receptor antagonist (ARB) of therapy dose and one of active metabolites or pharmaceutically acceptable salts thereof, one or several of B vitamins of therapy dose, gingo biloba extract (GbE) of therapy dose and pharmacy acceptable carriers and application of the pharmaceutical composition in preparing pharmaceuticals used for treating, preventing or delaying brain stroke. The pharmaceuticals prepared from the pharmaceutical composition is superior to simple antihypertensive drugs in the aspect of treating, preventing or delaying brain stroke diseases, and oral use becomes more convenient for patients. The invention belongs to the pharmacy field.

The invention discloses an antihypertensive composition comprising amlodipine besylate and consists of the components with the following weight ratios: 1 portion of amlodipine besylate and 2 to 8 portions of indapamide which both have the antihypertensive effect, but more adverse reactions are produced when the amlodipine besylate or the indapamide is used respectively. The invention which combines the amlodipine besylate and the indapamide which can have a better synergistic effect in a certain proportion scope not only can reduce the adverse reactions and the doses but also has significant antihypertensive effects, wide application prospects and worth popularization.

The invention relates to the technical field of Chinese medicine beverage health products and particularly relates to a step-down health product and a preparation method of the step-down health product. The step-down health product comprises the following raw materials or extracts thereof: sophora flower bud extract, gastrodia elata, concha haliotidis, chrysanthemum, tuckahoe, the root of kudzu vine, forsythia suspense, jasmine, fructus amomi, wolfberry fruit, orange peel, hawthorn, polygala root, jujube kernel, red sage, uncaria rhynchophylla and tu-chung. The Chinese medicine step-down health product is finally prepared by cleaning, drying, crushing and decocting the raw materials. By adopting the step-down health product and the preparation method of the step-down health product, the problem of incapability of common hypotensive drugs for thoroughly and radically treating hypertension except for relieving medications is effectively solved; by clearing away heat and toxic materials, calming liver, refreshing brain, reducing blood pressure, promoting blood circulation to remove blood stasis and nourishing liver and kidney, the step-down health product completely regulates the human body from the root causes of hypertension so as to increase the activity of the human cells, radically reverse the pathogenesis of hypertension, effectively relieve the pain of patients suffering from hypertension, relieve the pain of patients for continuous medication and effectively reduce the economic pressure of patients.

The invention relates to a beta-adrenergic receptor retarder (short for beta receptor retarder) and vitamins B-containing pharmaceutical composition which comprises effective treatment quantity of one of beta receptor retarder and an active metabolite or salt thereof, effective treatment quantity of one or more of vitamins B, and a pharmaceutically acceptable carrier, wherein the content of the beta receptor retarder and the active metabolite or salt thereof is 2.5-200mg, and the content of vitamins B is 0.1-50mg. The beta-adrenergic receptor retarder and vitamins B-containing pharmaceutical composition has the advantages that with the pharmaceutical composition, the curative effect of the beta receptor retarder on reducing the blood pressure can be enhanced, the target organ protection role of the beta receptor retarder hypotensive drugs can be enhanced, and the occurrence rate of complications such as left ventricular hypertrophy, coronary heart disease, heart failure, cerebral apoplexy, renal lesions, renal insufficiency and the like can be reduced. In addition, the pharmaceutical composition can enable patients to take conveniently, and the medical cost can be lowered.

The invention discloses an antihypertensive drug composition, a preparation method of the antihypertensive drug composition and an antihypertensive device using the antihypertensive drug composition. The antihypertensive drug composition comprises, by weight, raw materials of 15-25 parts of virgin soil, 15-25 parts of monkshood, 25-35 parts of fructus evodiae and 7-13 parts of live leech. The preparation method comprises smashing the virgin soil, the monkshood and the fructus evodiae to obtain dry powder; soaking the live leech by using alcohol, grinding the alcohol and the live leech to form slurry, adding the dry powder, soaking for more than 15 days, dying in a vacuum mode to obtain the antihypertensive drug composition. The antihypertensive device comprises an electric pulse generator, an antihypertensive paste and a lead connected between the output end of the electric pulse generator and the antihypertensive paste, and the antihypertensive paste comprises adhesive plaster and a drug bag which is arranged on a pasting face of the adhesive plaster and filled with the antihypertensive drug composition. The antihypertensive drug composition is simple in prescription and wide in raw material resource, and is an effective external use antihypertensive drug. A preparation process is simple and easy to control, and no complex equipment is needed. The antihypertensive device is simple in structure and can effectively reduce blood pressure through acupoint pressing, drug permeation and electric pulse stimulation.

The invention belongs to the field of chemical synthesis of drugs, and particularly relates to a preparation method of a hypotensive drug benidipine hydrochloride. The method comprises the following steps: carrying out a Knoevenagel reaction, a Michael addition reaction, cyclization and hydrolysis on starting raw materials 3-nitrobenzaldehyde and methyl acetoacetate in the presence of a catalyst, reacting with thionyl chloride, directly reacting with 1-benzyl-3-hydroxypiperidine, and refining to obtain the benidipine hydrochloride. The benidipine hydrochloride obtained by adopting the preparation method of the benidipine hydrochloride is high in purity, column chromatography isolation is not needed, and the HPLC purity of the product is 99.5% or above. The yield of the obtained benidipine hydrochloride is relatively high and can reach 68% or above.

The invention discloses preparation equipment of a hypotensive drug. The hypotensive drug comprises the following components in parts by weight: 7-13 parts of Chinese dates, 2-5 parts of cordyceps militaris, 1-2 parts of ginseng, 2-8 parts of Chinese wolfberry fruits, 5-11 parts of white gourds, 10-20 parts of cassia seeds, 8-15 parts of kudzuvine roots, 3-7 parts of chrysanthemums, 6-14 parts of Chinese yams, 1-3 parts of corn stigma, 10-25 parts of rhizoma polygonati and 5-10 parts of cape jasmine fruits. In order to prepare the antihypertensive drug, the antihypertensive drug comprises a crushing assembly, an extraction assembly, a granulation assembly and a packaging assembly, the crushing assembly comprises a crushing device, a feeding device and a stirring device, the extraction assembly comprises an extraction tank, a feeding hole of the extraction tank is communicated with the stirring device, and the granulation assembly comprises drying equipment. The crushing assembly can crush different raw materials into materials with different thicknesses according to requirements, the materials are evenly mixed through the stirring device, then the materials are extracted through the extraction assembly, finally drying, concentration and compression molding are conducted, and tablets with specific shapes are obtained and packaged.

The invention discloses an application of a chondriokinesis inhibitor in preparation of medicines for preventing and treating hypertension, belonging to the technical field of biological medicines. The research proves that the chondriokinesis activity of blood vessels participates in vasotonia generation, and due to inhibition of chondriokinesis of blood vessels, vasoconstriction induced by phenylephrine and high potassium fluid can be obviously relaxed. According to a chondriokinesis inhibitor Mdivi-1 of which the structural formula is shown in a formula I, the vasoconstriction induced by phenylephrine and high potassium fluid can be obviously relaxed, so that the animal blood pressure is reduced. On the basis, the invention provides a method for screening novel hypotensive drugs and a novel application of the chondriokinesis inhibitor serving as a novel hypotensive drug. According to the application provided by the invention, a novel technical means is provided for prevention and treatment of hypertension. The structural formula is as shown in the specification.

The invention relates to the preparation field of a single configuration of a hypotensive drug (R)-cilnidipine, in particular to a preparation method of a hypotensive drug (R)-cilnidipine. The preparation method comprises the following steps: 1) adding ethyl cyano acetoacetate, m-nitrobenzaldehyde, 3-amino-2-methoxyethyl butenoate into isopropanol for a reflux reaction to obtain a racemized product; 2) adding the racemized product into an aqueous solution, adding lipase as a catalyst to stir for a catalytic reaction, and after reaction, acidifying and filtering a reaction liquid to obtain (R)-1,4-dihydrogen-2,6-dimethyl-4-(3-nitryl phenyl)-3,5-dipicolinic acid-5-(2-methoxyl ethyl); and 3) carrying out an esterification reaction with cinnamyl alcohol to obtain (R)-cilnidipine. The method provided by the invention obtains (R)-cilnidipine with high selectivity and high yield, and ee% reaches up to 99.7%.

The invention relates to a medicament composition containing biguanide antidiabetic medicament, ACEI (Angiotensin-Converting Enzyme Inhibitors) medicament and a pharmaceutically acceptable carrier. The invention also relates to the applications of the medicament composition in the preparation of medicaments for preventing or treating diabetes mellitus with hypertension. The implementation of the invention provides the medicament composition with specific applications, and the medicament composition not only has a precise curative effect, but also can improve the compliance of patients. The patients can take the medicament conveniently, and the medical expense is reduced. The invention has a better market prospect, and belongs to the field of pharmacy.

The invention discloses a preparation process of a hypotensive drug optically pure cilnidipine. The preparation process comprises the following steps: 1) in the presence of (S)-BINAP and a ferric ironcompound, adding ethyl cyano acetoacetate, m-nitrobenzaldehyde and 3-amino-2-methoxyethyl butenoate into isopropanol to react to obtain (R)-1,4-dihydro-2,6-dimethul-4-(3-nitryl phenyl)-3,5-dipicolinic acid-3-(2-cyano ethyl ester)-5-(2-methoxyl ethyl ester); 2) stirring the product in a tetrahydrofuran aqueous solution of alkali to react to obtain (R)-1,4-dihydro-2,6-dimethyl-4-(3-nitryl phenyl)-3,5-dipicolinic acid-5-(2-methoxyl ethyl ester); and 3) carrying out an esterification reaction with cinnamyl alcohol to obtain the optically pure (R)-cilnidipine. The three-step yield of the (R)-cilnidipine reaches up to 41%, ee% reaches up to 99.5%, and the preparation process is simple and suitable for industrial production.

The invention relates to a triple-hypertensive pharmaceutical composition. The triple-hypertensive pharmaceutical composition comprises the following components in therapeutically effective amount: 2mg-240mg of a calcium antagonist (CCB), 1.25mg-75mg of an angiotensin converting enzyme inhibitor (ACEI) and 0.4mg-1.6mg of folic acid compounds. The triple-hypertensive pharmaceutical composition has the advantages that the antihypertensive therapy effects of patients with 2-3-level hypertension can be effectively improved, the protection to target organs of the patients is enhanced, and the risk of complication of cerebral apoplexy caused by the hypertension is reduced; and besides, the triple-hypertensive pharmaceutical composition is easily taken by the patients, the treatment compliance is greatly improved, and the medical expense can be further lowered.

The present invention provides uses of combined application of a calcium antagonist drug and a 5-HT1A receptor agonist drug in preparation of drugs for treatment and prevention of high blood pressure,and a blood pressure lowering pharmaceutical composition, which comprises a therapeutically effective amount of a calcium antagonist and an active metabolite thereof, a therapeutically effective amount of a 5-HT1A receptor agonist and an active metabolite thereof, and a pharmaceutically acceptable carrier. According to the present invention, through the combined application of the calcium antagonist drug and the 5-HT1A receptor agonist drug, the blood pressure lowering effect can be significantly enhanced, and the side effect of the calcium antagonist can be reduced; and particularly comparedto the combined medication, the application of the compound preparation made of the calcium antagonist and the 5-HT1A receptor agonist as the blood pressure lowering drug can achieve the unexpected blood pressure lowering effect and reduce calcium antagonist induced side effects including constipation and tachycardia.

The invention discloses a high blood pressure therapy machine with pressure waves. The high blood pressure therapy machine mainly comprises a pressure wave generating device, wherein in a liquid medium, high voltage electropulse is released and generates the pressure waves which focus on certain portions of the limbs or acupoints, and the pressure wave generating device is selected from one of an electromagnetic effect pressure wave pulse generating device body, a hydroelectric effect pressure wave pulse generating device body and a piezoelectric effect pressure wave pulse generating device body. According to the high blood pressure therapy machine, the pressure waves are utilized to stimulate certain portions of the limbs or acupoints, so that the blood circulating system of the human tissues is affected, high blood pressure is lowered or made to reach the normal value, a patient reduces the dosage of hypotensive drugs or maintains a normal blood pressure without taking medicine for a long time, and thus the purpose of treatment is achieved.

The invention relates to a compound hypotensive tablet and a preparation method thereof. Particularly, the invention relates to a pharmaceutical composition. The pharmaceutical composition comprises the following raw materials in parts by weight: 0.1 part of reserpine, 10-15 parts of hydrochlorothiazide, 10-15 parts of triamterene and 10-15 parts of dihydralazine sulfate. The invention further relates to a method for preparing the pharmaceutical composition. Furthermore, the invention further relates to a method for stabilizing the pharmaceutical composition in a tablet form. The method comprises a step of adding saccharides and starch additives to the pharmaceutical composition. The pharmaceutical composition comprises the reserpine, the hydrochlorothiazide, the triamterene and the dihydralazine sulfate. The compound hypotensive tablet is generally called Beijing hypotensive No.0 or No.0 in the field, is an excellent hypotensive drug which is accurate in curative effect, low in bad reaction and low in price, and has excellent pharmaceutical properties.

The invention relates to a method for preparing dihydropyridine compounds. In the method, compound II is used as a raw material to carry out demethylation reaction in methanesulfonic acid to prepare dihydropyridine compound I. Compared with the prior art, the raw materials of the deprotection reagent used in the present invention are easy to obtain, the reaction and post-treatment are simple and convenient, the environmental pollution is small, and it is suitable for industrial production; the present invention has high yield, stable product quality, low cost, simple operation, and is suitable for reducing Industrial preparation of key intermediates of clevidipine butyrate for pressing.

The invention relates to the depressurization active part extracts of Hebei chrysanthemum, the preparing method and its application in the medical preparation is also mentioned in the invention. The extract is obtained through adsorbing the extracted solution by macroporous resin and eluting by alcohol (less than 60%). The preparing procedure includes the following steps: getting the extracted solution from Hebei chrysanthemum with routine method; adsorbing and eluting the solution, the eluting solution is alcohol (the density of which is smaller than 60%); collecting the eluted solution; condensing and drying. The extract can be used as the active ingredient to prepare different kinds of pharmaceutical dosage forms such as soft capsule, pellet, dripping pills, injectable preparation and slowly controlled releasing dosage. The invention has provided a new and steady hypotensive drug for clinical use.

The invention discloses a hypotensive drug bulk drug formula with good effect, which comprises the following raw material composition by weight ratio: Qingsong 1-5 parts, cassia 11-19 parts, semen Lepidii 5-7 parts, 3-5 parts of sweet-scented osmanthus, Gentiana macrophylla 5-10 parts, hawthorn 25-35, 20-30 parts cassia seeds, Alisma orientalis 10-18 part, 10- 20 parts of polygonum cuspidatum, 9-16 parts of yinchaihu, 5-10 parts, ghost arrows 10-15 parts. The antihypertensive medicine with good effect not only has good effect on prevention and treatment of hypertension, but also has short course of treatment and quick effect, in particular, the side effect is small, the harm to the patient is little, and the taste is good.